GSDME and hepatocellular carcinoma: Miltirone inhibits HCC progression by targeting GSDME-induced pyroptosis, significantly increasing intracellular ROS accumulation while inhibiting MAPK activation and mitogen-activated protein kinase/extracellular signal-regulated kinase phosphorylation, which collectively inhibit the activity of extracellular signal-regulated kinase 1/2 (ERK1/2).